Recently, the market market for innovative drugs and CXO sectors has continued to be interpreted. The rebound in the sector has accelerated the return of the net worth of a number of pharmaceutical-themed funds. In the past three months, many pharmaceutical industry funds have rebounded sharply, with a net worth growth rate of more than 30%. According to institutional investors, the pharmaceutical market is undergoing a logical shift, gradually shifting from valuation repair to cross-verification of clinical data, BD transaction fulfillment, and order growth. Whether the market can continue after judging, we need to keep a close eye on multiple variables such as clinical data, capital games, and industrial policies.

Recently, the market market for innovative drugs and CXO sectors has continued to be interpreted. The rebound in the sector has accelerated the return of the net worth of a number of pharmaceutical-themed funds. In the past three months, many pharmaceutical industry funds have rebounded sharply, with a net worth growth rate of more than 30%. According to institutional investors, the pharmaceutical market is undergoing a logical shift, gradually shifting from valuation repair to cross-verification of clinical data, BD transaction fulfillment, and order growth. Whether the market can continue after judging, we need to keep a close eye on multiple variables such as clinical data, capital games, and industrial policies.